Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antifolate Resistance Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GGH drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GGH Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View GGH Products |
| Gene Delivery | GGH Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View GGH Products |
| Benchmark Ab | Anti-GGH Recombinant Antibody High-specificity positive control for ELISA, Western Blot, and Flow Cytometry. |
View GGH Products |
| Validator | GGH siRNA Set For knockdown verification and functional gene-silencing assays. |
View GGH Products |
| Related Target A | FPGS (Folylpolyglutamate Synthase) The antagonist enzyme of GGH; critical for balancing folate/antifolate cellular retention. |
View FPGS Products |
| Related Target B | DHFR (Dihydrofolate Reductase) Downstream therapeutic target of methotrexate; directly modulated by GGH activity. |
View DHFR Products |
| Related Target C | TYMS (Thymidylate Synthase) Key target of pemetrexed; synergy evaluations with GGH inhibition. |
View TYMS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity validation & inhibitor screening | HEK293-expressed GGH ensures native folding and glycosylation, crucial for accurate in vitro cleavage assays. |
| Specificity & cross-reactivity screening | Human/Mouse/Cyno ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant controls included. |
| False Positives in Knockdown | Multiple-target siRNA pools included for highly specific target validation. |
Live GGH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GGH therapeutics is intensifying, with major players shifting focus from traditional chemotherapy support to overcoming drug resistance in solid tumors and hematological malignancies. As first-generation therapies reach the clinic, the next wave of R&D is targeting GGH small molecule inhibitors and companion diagnostics to rescue the efficacy of antifolates like methotrexate and pemetrexed.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Oncology Biotechs | Acute Lymphoblastic Leukemia (ALL), Breast Cancer | High-throughput screening assays (Need high-purity, enzymatically active recombinant GGH) |
| Antibody-Drug Conjugates (ADC) | Emerging Biotech Startups | Solid Tumors (Overexpressing GGH) | Internalization Assay & Specificity validation (Need native conformation GGH ECD-Fc) |
| Combination Therapies (with Antifolates) | Global Pharmaceutical Corporates | Non-Small Cell Lung Cancer (NSCLC), Mesothelioma | Synergy validation in vitro (Need stable GGH-overexpressing cell lines via Lentivirus) |